A prospective study: evaluation of the antibody-dependent cell-mediated cytotoxicity assay in chronic active Epstein-Barr syndrome.
Prospective monitoring of active Chronic Epstein-Barr virally infected patients receiving gammaglobulin therapy was performed using the antibody-dependent cell-mediated cytotoxicity assay (ADCC). Efforts were made to analyze and define with respect to clinical course the autologous immunological parameters (cells and sera). Our data demonstrate that the diagnosis and clinical course of this syndrome proved inconsistent with the assays usefulness in predicting suggestive benefits of gammaglobulin therapy.